Zacks Investment Research upgraded shares of Medicure Inc. (OTCMKTS:MCUJF) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. Zacks Investment Research currently has $7.00 price objective on the stock.
According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “
Separately, ValuEngine upgraded Medicure from a buy rating to a strong-buy rating in a report on Saturday, June 17th.
Medicure (OTCMKTS:MCUJF) opened at 6.24 on Thursday. Medicure has a 52 week low of $4.11 and a 52 week high of $7.96. The company has a market cap of $97.13 million, a PE ratio of 6.14 and a beta of 0.59. The company’s 50-day moving average price is $6.41 and its 200 day moving average price is $6.38.
TRADEMARK VIOLATION NOTICE: “Medicure Inc. (MCUJF) Upgraded to Buy at Zacks Investment Research” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://transcriptdaily.com/2017/08/13/medicure-inc-mcujf-upgraded-to-buy-at-zacks-investment-research.html.
Medicure Company Profile
Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.